Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Mineralys Therapeutics, Inc. - Common Stock
(NQ:
MLYS
)
27.06
-0.29 (-1.08%)
Streaming Delayed Price
Updated: 3:02 PM EDT, Aug 10, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Mineralys Therapeutics, Inc. - Common Stock
< Previous
1
2
3
Next >
A Mineralys Insider Banked a $557,000 Options Gain Before a December FDA Date
↗
July 16, 2026
This executive exercised 20,407 options at $1.08 and immediately sold them at $27.28 per share.
Via
The Motley Fool
Topics
Regulatory Compliance
What to Know About This Mineralys Insider Sale Before a December FDA Date
↗
July 16, 2026
Insider divested 2% of direct holdings via pre-planned Rule 10b5-1 trading arrangement, following a 90% stock surge over the past year.
Via
The Motley Fool
Topics
Regulatory Compliance
What a $350,000 Insider Sale Might Mean for Mineralys Ahead of December FDA Decision
↗
June 23, 2026
This clinical-stage biotech focused on hypertension therapies reported a notable insider sale amid strong one-year stock performance.
Via
The Motley Fool
Topics
Regulatory Compliance
Mineralys Therapeutics Inc (NASDAQ:MLYS) First Quarter 2026 Results Show Modest Market Reaction to FDA NDA Acceptance
↗
May 06, 2026
Via
Chartmill
Mineralys Therapeutics Inc (NASDAQ:MLYS) Reports Q4 2025 EPS Beat and Key FDA NDA Acceptance for Lorundrostat
↗
March 12, 2026
Via
Chartmill
Earnings Scheduled For November 10, 2025
↗
November 10, 2025
Via
Benzinga
Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million
↗
May 31, 2026
Mineralys Therapeutics develops novel therapies for resistant hypertension, with its lead candidate advancing through clinical trials.
Via
The Motley Fool
Topics
Regulatory Compliance
Mineralys (MLYS) Q1 2026 Earnings Transcript
↗
May 06, 2026
Mineralys (MLYS) Q1 2026 Earnings Transcript
Via
The Motley Fool
Mineralys Therapeutics' CEO Sold Shares Worth $1.97 Million. Should Investors Avoid the Stock?
↗
April 07, 2026
This clinical-stage biotech focused on hypertension therapies reported a notable insider sale, according to new SEC filings.
Via
The Motley Fool
Topics
Regulatory Compliance
Cancer Drug Maker With $172 Million Revenue and Multiple Approved Therapies Draws $6.5 Million Investment
↗
March 13, 2026
This clinical-stage biotech develops oncology therapeutics and partners with leading institutions in cancer and immunology research.
Via
The Motley Fool
Topics
Regulatory Compliance
Biotech Stock Up 365% as This $8 Million Investment Targets a Drug With 3 NDA Filings Planned
↗
March 13, 2026
This biotech specializes in precision therapies for rare genetic diseases, with a pipeline targeting oncology and hematology indications.
Via
The Motley Fool
Topics
Regulatory Compliance
Mineralys (MLYS) Q4 2025 Earnings Call Transcript
↗
March 12, 2026
Mineralys (MLYS) Q4 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Fund Discloses Increased Mineralys Bet Amid 200% Stock Run as New Drug Application Nears
↗
December 23, 2025
When a clinical-stage biotech is sitting on nearly $600 million in cash and lining up an FDA filing, sharp investors stop arguing about the past rally and start debating what comes next.
Via
The Motley Fool
Topics
Regulatory Compliance
This Fund Leaned Into 2025's Big Biotech Rally with a $9.5 Million Bet on Mineralys
↗
November 27, 2025
One small fund’s high-conviction move offers a window into how specialists are navigating 2025’s biotech rally.
Via
The Motley Fool
Topics
Regulatory Compliance
MINERALYS THERAPEUTICS INC (NASDAQ:MLYS) Beats Q3 2025 EPS Estimates and Advances Key Drug Candidate
↗
November 10, 2025
Mineralys Therapeutics beat Q3 2025 EPS estimates. The biotech firm is advancing its lead drug, lorundrostat, toward a planned FDA submission.
Via
Chartmill
Uncovering Potential: Mineralys Therapeutics's Earnings Preview
↗
November 07, 2025
Via
Benzinga
These 2 Healthcare Stocks Are Up Over 100% in a Month. Can They Keep Climbing?
↗
September 21, 2025
Here's what needs to happen for these high flyers to continue soaring.
Via
The Motley Fool
It's a Small World: 3 Stocks Leading the Sudden Rebound in Small Caps
↗
September 16, 2025
A new market leader has snuck into town over the past month as Small Caps have pushed to the top of the leader board. Whether the trend lasts, or not, will depend a lot on what the Fed does, but one...
Via
The Motley Fool
Topics
Economy
Stocks
These 2 Healthcare Stocks More Than Doubled Recently and Could Soar Higher, According to Wall Street Analysts
↗
September 07, 2025
Experts who follow these stocks think they can fly higher despite already gaining over 100% since the end of July.
Via
The Motley Fool
Bruker, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
↗
September 03, 2025
Via
Benzinga
Why Alphabet Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
↗
September 03, 2025
Via
Benzinga
Here are the top movers in Tuesday's session.
↗
September 02, 2025
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.
Via
Chartmill
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
September 02, 2025
Via
Benzinga
Top movers analysis in the middle of the day on 2025-09-02: top gainers and losers in today's session.
↗
September 02, 2025
Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.
Via
Chartmill
Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
↗
September 02, 2025
Via
Benzinga
There are notable gap-ups and gap-downs in today's session.
↗
September 02, 2025
The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
Via
Chartmill
Nasdaq Down 1%; Signet Jewelers Earnings Top Views
↗
September 02, 2025
Via
Benzinga
Tuesday's pre-market session: top gainers and losers
↗
September 02, 2025
As we await the opening of the US market on Tuesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Via
Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
September 02, 2025
Via
Benzinga
Why Carisma Therapeutics Shares Are Trading Higher By 133%; Here Are 20 Stocks Moving Premarket
↗
September 02, 2025
Via
Benzinga
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
